Azacitidine: A novel agent for myelodysplastic syndromes

14 Christman JK, Mendelsohn N, Herzog D et al. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res. 1983; 43:763Ò9.
15 Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem. 1982; 257:2041Ò8.
16 Ley TJ, DeSimone J, Anagnou NP et al. 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta+thalassemia. N Engl J Med. 1982; 307:1469Ò75.
17 Kizaki M, Koeffler HP. Differentiation-inducing agents in the treatment of myelodysplastic syndromes. Semin Oncol. 1992; 19:95Ò105
18 Silverman LR. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist. 2001; 6(suppl 5):8Ò14.
19 Robertson KD, Jones PA. DNA methylation: past, present and future directions. Carcinogenesis. 2000; 21:461Ò7.
20 Quesnel B, Guillerm G, Vereecque R et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998; 91:2985Ò90
21 Uchida T, Kinoshita T, Nagai H et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997; 90:1403Ò9.
22 Silverman LR, Zinar S, Holland JF. Azacytidine acts as a biologic response modifier on hematopoietic cell response to cytokines. Proc Am Assoc Cancer Res. 1998; 39:405.
23 Troetel WM, Weiss AJ, Stambaugh JE et al. Absorption, distribution, and excretion of 5-azacytidine (NSC 102816) in man. Cancer Chemother Rep. 1972; 56:405Ò11.
24 Silverman LR, Holland JF, Weinberg RS et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993; 7(suppl 1):21Ò9.
25 Silverman L, Holland JF, Demakos E et al. Azacytidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann Hematol. 1994; 12.
26 Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20:2429Ò40.
27 Kornblith AB, Herndon JE II, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20:2441Ò52.
28 Schiffer CA, Anderson K, Coleman M et al. Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacytidine administered by continuous infusion: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1985; 69:1027Ò8.
29 Bellet RE, Mastrangelo MJ, Engstrom PF et al. Hepatotoxicity of 5-azacytidine (NSC 102816): a clinical and pathologic study. Neoplasma. 1973; 20:303Ò9.
30 Red book update. Montvale, NJ: Medical Economics; 2004:10.
31 Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic splastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18:956Ò62.
32 Saba HI, Rosenfeld CS, Issa J et al. Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs supportive care (SC) in patients with advanced myelodysplastic syndrome (MDS). Presented at 2005 ASCO Annual Meeting.